Elaboração de Manual de Orientações sobre Hipertermia Maligna para Pacientes

Autores

DOI:

https://doi.org/10.34024/rnc.2021.v29.12345

Palavras-chave:

Hipertermia Maligna, Educação em saúde, Prevenção

Resumo

Introdução. Hipertermia Maligna (HM) é doença farmacogenética, desencadeada pela exposição de indivíduos susceptíveis a anestésicos voláteis e succinilcolina. Excepcionalmente, crises são desencadeadas por exercício e calor ambiental.  Esse estado hipermetabólico manifesta-se por hipercapnia, taquicardia, rigidez muscular, acidose lática e hipertermia; sem tratamento específico, mortalidade alcança 70-80%. Fora da crise, geralmente o paciente é assintomático, mas raramente apresenta intolerância ao esforço, cãibras musculares ou sinais de miopatia. Artigos/livros e sites informam profissionais de saúde e leigos sobre diagnóstico de HM com teste de contratura muscular in vitro e genética, além do tratamento da crise de HM com dantrolene, mas não estão disponíveis informações para período intercrítico. Objetivo. Elaboração de manual de orientações para os susceptíveis à HM, quanto aos cuidados na vida diária. Método. O manual de orientações fundamentou-se em revisão bibliográfica sobre repercussões da susceptibilidade à HM, realizada segundo diretrizes do QUORUM e do Grupo de Trabalho de Medicina Baseada em Evidências. Resultados. A revisão localizou 129 artigos que foram analisados e permitiram a elaboração de 14 perguntas relacionadas a cuidados com exercício, diagnóstico pré-natal, manejo de doenças associadas pré-existentes (diabetes mellitus, asma brônquica), intoxicações exógenas, drogas ilícitas, tratamento odontológico, e medicações (serotoninérgico, quinolona, anti-dislipidêmico, contraste iodado, inibidor de fosfodiesterase III, bloqueador de canal de cálcio, betabloqueador, neuroléptico, heparina). As informações foram vertidas para linguagem leiga e usadas no manual de orientação disponibilizado online (https://cedhima.unifesp.br). Conclusão. Apesar da HM ser conhecida pela crise anestésica, há implicações na vida diária que devem ser divulgadas para pacientes e profissionais de saúde.

Downloads

Não há dados estatísticos.

Referências

Rosenberg H, Sambuughin N, Riazi S, Dirksen R. Malignant Hyperthermia Susceptibility. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al (eds.). GeneReviews®. Seattle: University of Washington; 2020. https://pubmed.ncbi.nlm.nih.gov/20301325/

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;27:1896-900. https://doi.org/10.1016/s0140-6736(99)04149-5

Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The Oxford Levels of Evidence 2 (endereço na internet). Oxford Centre for Evidence-Based Medicine acessado em 2021). Disponível em: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence

Centro de Estudos, Diagnóstico e Investigação de Hipertermia Maligna (endereço na internet). São Paulo: Unifesp. www.cedhima.unifesp.br

Rodrigues G, Amaral JLG, Silva HCA. Hipertermia Maligna Manual de Orientação. Registro Câmara Brasileira do Livro nº DA-2020-004537. https://cedhima.unifesp.br/images/HMManual.pdf

Rodrigues G. Pacientes com Hipertermia Maligna: Estudo do Impacto da Doença e Elaboração Preliminar do Manual de Orientação (Tese). São Paulo: Universidade Federal de São Paulo; 2010. http://repositorio.unifesp.br/handle/11600/19356.

Rodrigues G. Aplicabilidade de manual de orientação via internet para doença rara hipertermia maligna (Tese). São Paulo: Universidade Federal de São Paulo; 2021.

Moreira MF, Nobrega MML, Silva MIT. Comunicação escrita: contribuição para a elaboração de material educativo em saúde. Rev Bras Enferm 2003;56:184.

https://doi.org/10.1590/S0034-71672003000200015

Gerdes C, Richter A, Annies R, Löscher W. Increase of serotonin in plasma during onset of halothane-induced malignant hyperthermia in pigs. Eur J Pharmacol 1992;10:91-4. https://doi.org/10.1016/0014-2999(92)90016-w

Wappler F, Fiege M, Schulte am Esch J. Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth 2001;87:783-7. https://doi.org/10.1093/bja/87.5.794

Ooms L, Awouters F, Degryse A, Jageneau T. Serotonin and S2 antagonists in veterinary medicine. In: Ruckebusch Y, Toutain P-L, Koritz GD (eds). Veternary Pharmacolog and Toxicology. Boston: MTP Press; 1983; p263-81.

https://link.springer.com/chapter/10.1007/978-94-009-6604-8_28

Stanley TH, Port JD, van der Maantin J, Kimball J. Treatment of stress hyperthermia in elk with ketanserin, a serotonin receptor blocker. Vet Surg 1986;15:214-7.

https://doi.org/10.1111/j.1532950X.1986.tb00208.x

Loscher W, Witte U, Fredow G, Ganter M, Bick K. Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT 2 receptors induces malignant hyperthermia. Naunyn-Schmiedebergs Arch Pharmacol 1990;341:483-93. https://doi.org/10.1007/BF00171727

Wappler F, Roewer N, Kochling A, Scholz J, Loscher W, Steinfath M, et al. Effects of the Serotonin2 Receptor Agonist DOI on Skeletal Muscle Specimens from Malignant Hyperthermia-susceptible Patients. Anesthesiology 1996;84:1280–7.

https://doi.org/10.1097/00000542-199606000-00002

Gener B, Burns JM, Griffin S, Boyer EW. Administration of ondansetron is associated with lethal outcome. Pediatrics 2010;125:1514-7. https://doi.org/10.1542/peds.2009-2795

Wappler F, Scholz J, von Richthofen V, Fiege M, Köchling A, Lambrecht W, et al. Attenuation of serotonin-induced contractures in skeletal muscle from malignant hyperthermia-susceptible patients with dantrolene. Acta Anaesthesiol Scand 1997;41:1312-8. https://doi.org/10.1111/j.1399-6576.1997.tb04650.x

Wappler F, Scholz J, Oppermann S, von Richthofen V, Steinfath M, Schulte am Esch J. Ritanserin attenuates the in vitro effects of the 5-HT2 receptor agonist DOI on skeletal muscles from malignant hyperthermia-susceptible patients. J Clin Anesth 1997;9:306-11. https://doi.org/10.1016/s0952-8180(97)00008-1

Wappler F, Scholz J, Fiege M, Richter A, Steinfath M, Weisshorn R, et al. 5-HT2 receptor antagonist-mediated inhibition of halothane-induced contractures in skeletal muscle specimens from malignant hyperthermia susceptible patients. Naunyn Schmiedebergs Arch Pharmacol 1999;360:376-81.

https://doi.org/10.1007/s002109900062

Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. In: StatPearls. Treasure Island: StatPearls Publishing; 2020. https://www.ncbi.nlm.nih.gov/books/NBK554406/

Johannsen S, Roewer N, Schuster F. Ondansetron-induced muscular contractures in malignant hyperthermia-susceptible individuals. Anesth Analg 2012;115:925-8.

https://doi.org/10.1213/ANE.0b013e31825d3749

Alós JI. Quinolonas. Enferm Infecc Microbiol Clin 2003:21:261-8. https://doi.org/10.1016/s0213-005x(03)72932-2

Metterlein T, Schuster F, Tadda L, Hager M, Muldoon S, Capacchione J, et al. Fluoroquinolones influence the intracellular calcium handling in individuals susceptible to malignant hyperthermia. Muscle Nerve 2011;44:208-12. https://doi.org/10.1002/mus.22021

Guis S, Bendahan D, Kozak-Ribbens G, Mattei JP, Le Fur Y, Confort-Gouny S, et al. Investigation of fluoroquinolone-induced myalgia using (31)P magnetic resonance spectroscopy and in vitro contracture tests. Arthritis Rheum 2002;46:774-8. https://doi.org/10.1002/art.10094

Denborough MA. Heat stroke and malignant hyperpyrexia. Med J Aust 1982;i:204-5. https://doi.org/10.5694/j.1326-5377.1982.tb132267.x

Figarella-Branger D, Kozak-Ribbens G, Rodet L, Aubert M, Borsarelli J, Cozzone PJ, et al. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromus Dis 1993;3:553-6. https://doi.org/10.1016/0960-8966(93)90114-Y

Bendahan D, Kozak-Ribbens G, Confort-Gouny S, Ghattas B, Figarella-Branger D, Aubert M, et al. A Noninvasive Investigation of Muscle Energetics Supports Similarities Between Exertional Heat Stroke and Malignant Hyperthermia. Anest Analg 2001;93:683-9. https://doi.org/10.1097/00000539-200109000-00030

Wappler F, Fiege M, Steinfath M, Agarwal K, Scholz J, Singh S, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001;94:95-100. https://doi.org/10.1097/00000542-200101000-00019

Davis M, Brown R, Dickson A, Horton H, James D, Laing N, et al. Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. Br J Anaesth 2002;88:508-15. https://doi.org/10.1093/bja/88.4.508

Kozak-Ribbens G, Rodet L, Petrognani R. Hiperthermie d’effort (HE); résultats des explorations de 55 patients. In: Novelli GP, Tegazzin V (eds.). Workshop in Anaesthesia and Pharmacogenic Disease: malignant hyperthermia. Minerva Anestesiol 1994;60(suppl 3):177-81.

Denborough MA. Malignant hyperthermia. The Lancet 1998;352:3. https://doi.org/10.1016/S0140-6736(98)03078-5

Hackl W, Winkler M, Mauritz W, Sporn P, Steinbereithner K. Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. Br J Anaesth 1991;66:138-40. https://doi.org/10.1093/bja/66.1.138

Hopkins P M, Ellis F R, Halsall P J. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet 1991;338:1491-2. https://doi.org/10.1016/0140-6736(91)92304-k

Watson DB, Gray GW, Doucet JJ. Exercise rhabdomyolysis in military aircrew: two cases and a review of aeromedical disposition. Aviat Space Environm Med 2000;71:1137-41.

https://pubmed.ncbi.nlm.nih.gov/11086669/

Pamukcoglu T. Sudden death due to malignant hyperthermia. Am J Forensic Med Pathol 1988;9:161-2.

https://doi.org/10.1097/00000433-198806000-00015

Ryan JF, Tedeschi LG. Sudden unexplained death in a patient with a family history of malignant hyperthermia. J Clin Anesth 1997;9;66-8. https://doi.org/10.1016/S0952-8180(96)00207-3

Köchling A, Wappler F, Winkler G, Esch J. Rhabdomyolysis following Severe Physical Exercise in a Patient with Predisposition to Malignant Hyperthermia. Anaesthes Inten Care 1998;26:315-8.

https://doi.org/10.1177/0310057X9802600317

Tobin JR, Jason DR, Challa VR, Nelson TE, Sambuughin N. Malignant Hyperthermia and Apparent Heat Stroke. JAMA 2001;286:168-9. https://doi.org/10.1001/jama.286.2.168

Campbell IT, Ellis FR, Evans RT, Mortimer MG. Studies of body temperatures, blood lactate, cortisol and free fatty acid levels during exercise in human subjects susceptible to malignant hyperpyrexia. Acta Anaesthesiol Scand 1983;27:349-55.

https://doi.org/10.1111/j.1399-6576.1983.tb01966.x

Hayward JS, Eckerson JD, Dawson BT. Effect of mesomorphy on hyperthermia during exercise in a warm, humid environment. Am J Phys Anthrop 1986;70:11-7.

https://doi.org/10.1002/ajpa.1330700104

Porter AMW. Collapse from exertional heat ilness: Implicationss and subsequente decisisons. Milit Med 2003;168:76-81. https://pubmed.ncbi.nlm.nih.gov/12546251/

Jacquot C, Stieglitz. Conduite à tenir devant um sujet susceptible de présenter une hyperthermie maligne em cãs d’anesthésie et dans la vie quotidienne Anaesthesia and counselling of malignant hyperthermia susceptible patients. Ann Fr Anesth Réanim 1989;8:417-26. https://doi.org/10.1016/S0750-7658(89)80008-5

London SF, Gross KF, Ringel SP. Cholesterol-lowering agent myopathy (CLAM). Neurology 1991;41:1159-60. https://doi.org/10.1212/wnl.41.7.1159

Meriggioli MN, Barboi AC, Rowin J, Cochran EJ. HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients. J Clin Neuromuscul Dis 2001;2:129-34. https://pubmed.ncbi.nlm.nih.gov/19078619/

Sharobeem KM, Madden BP, Millner R, Rolfe LM, Seymour CA, Parker J. Acute renal failure after cardiopulmonary bypass: a possible association with drugs of the fibrate group. J Cardiovasc Pharmacol Ther 2000;5:33-9. https://doi.org/10.1177/107424840000500105

Wilhelmi M, Winterhalter M, Fischer S, Walles T, Zuk J, Strüber M, et al. Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors. Cardiovasc Drugs Ther 2002;16:471-5. https://doi.org/10.1023/a:1022198705168

Guis S, Mattéi JP, Lioté F. Drug-induced and toxic myopathies. Best Pract Res Clin Rheumatol 2003;17:877-907.

https://doi.org/10.1016/j.berh.2003.11.002

Krivosic-Horber R, Dépret T, Wagner JM, Maurage CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol 2004;21:572-4. https://doi.org/10.1017/s0265021504227120

Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006;15;55:551-7. https://doi.org/10.1002/art.22100

Katiriji B, Al Jaberi MM. Creatine kinase revisited. J Clin Neuromuscul Dis 2001;2:158-64. https://doi.org/10.1097/00131402-200103000-00008

Vladutiu GD, Isackson PJ, Kaufman K, Harley JB, Cobb B, Christopher-Stine L, et al. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol Genet Metab 2011;104:167-73. https://doi.org/10.1016/j.ymgme.2011.07.001

Isackson PJ, Wang J, Zia M, Spurgeon P, Levesque A, Bard J, et al. RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms. Pharmacogenomics 2018;19:1235-49. https://doi.org/10.2217/pgs-2018-0106

Rosenberg H, Grant M. Ascending tonic-clonic syndrome secondary to intrathecal Omnipaque. J Clin Anesth 2004;16:299-300. https://doi.org/10.1016/j.jclinane.2004.03.002

Ong RO, Rosenberg H. Malignant hyperthermia-like syndrome associated with metrizamide myelography. Anesth Analg 1989;68:795-7. https://pubmed.ncbi.nlm.nih.gov/2735545/

Mozley PD. Malignant hyperthermia following intravenous iodinated contrast media. Report of a fatal case. Diagn Gynecol Obstet 1981;3:81-6. https://pubmed.ncbi.nlm.nih.gov/7011755/

Dunford J. Fatal ascending tonic-clonic seizure syndrome. Ann Emerg Med 1998;32:624-6. https://doi.org/10.1016/s0196-0644(98)70045-9

Rosenberg H, Antognini JF, Muldoon S. Testing for malignant hyperthermia. Anesthesiol 2002;96:232-7.

https://doi.org/10.1097/00000542-200201000-00036

Robinson RL, Monnier N, Wolz W, Jung M, Reis A, Nuernberg G, et al. A Genome Wide Search for Susceptibility Loci in Three European Malignant Hyperthermia Pedigrees. Hum Mol Gen 1997:6:953961. https://doi.org/10.1093/hmg/6.6.953

Robinson RL, Curran JL, Hall WJ, Halsall PJ, Hopkins PM, Markham AF, et al. Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families. J Med Genet 1998;35:196-201. https://doi.org/10.1136/jmg.35.3.196

Girard T, Jöhr M, Schaefer C, Urwyler A. Perinatal diagnosis of malignant hyperthermia susceptibility. Anesthesiology 2006;104:1353-4. https://doi.org/10.1097/00000542-200606000-00052

Suggested guidelines for management of the pregnant patient not believed to be at risk for MH, but whose partner is susceptible to malignant hyperthermia (endereço na Internet). acessado em 2012. https://www.mhaus.org/healthcare-professionals/mhaus-recommendations/parturient-with-mhs-partner/

Krivosic-Horber R, Adnet P, Krivosic I, Reyford H. Diagnostic de la sensibilité à l'hyperthermie maligne chez l'enfant [Diagnosis of susceptibility to malignant hyperthermia in children]. Arch Fr Pediatr 1990;47:421-4. https://pubmed.ncbi.nlm.nih.gov/2403268/

Stowell K, Pollock N, Langton E. Perinatal diagnosis of malignant hyperthermia susceptibility. Anaesth Inten Care 2007;35:454-5. https://pubmed.ncbi.nlm.nih.gov/17591153/

Robinson RL, Hopkins PM. A breakthrough in the genetic diagnosis of malignant hyperthermia. Br J Anaesth 2001;86:166-8. https://doi.org/10.1093/bja/86.2.166. doi: 10.1093/bja/86.2.166

O'Brien PJ, Klip A, Britt BA, Kalow BI. Malignant hyperthermia susceptibility: biochemical basis for pathogenesis and diagnosis. Can J Vet Res 1990;54:83-92. https://pubmed.ncbi.nlm.nih.gov/2155050/

Wynands JE. Amrinone: is it the inotrope of choice? J Cardiothorac Anesth 1989;3(6 Suppl 2):45-57. https://doi.org/10.1016/0888-6296(89)90059-8

Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Kolodzie K, Esch JS. Phosphodiesterase-III-inhibition with amrinone leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swine. Eur J Anaesthesiology 2005;22:283-8. https://doi.org/10.1017/s0265021505000475

Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Kolodzie K, Schulte Am Esch J. In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology 2003;98:944-9. https://doi.org/10.1097/00000542-200304000-00022

Riess FC, Fiege M, Moshar S, Bergmann H, Bleese N, Kormann J, et al. Rhabdomyolysis following Cardiopulmonary Bypass and Treatment with Enoximone in a Patient Susceptible to Malignant Hyperthermia. Anesthesiology 2001;94;355-7. https://doi.org/10.1097/00000542-200102000-00029

Fiege M, Wappler F, Scholz J, von Richthofen V, Brinken B, Schulte am Esch J. Diagnostik der Disposition zur malignen Hyperthermie durch einen in vitro Kontrakturtest mit dem Phosphodiesterase-III-Hemmstoff Enoximon [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone]. Anasthesiol Intensivmed Notfallmed Schmerzther 1998;33:557-63. https://doi.org/10.1055/s-2007-994811

Fiege M, Wappler F, Scholz J, Weisshorn R, von Richthofen V, Schulte am Esch J. Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients. J Clin Anesth 2000;12:123-8. https://doi.org/10.1016/s0952-8180(00)00124-0

Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens 2006;8:53-6. https://doi.org/10.1111/j.1524-6175.2005.04140.x

Foster PS, Denborough MA. Effect of diltiazem and dantrolene on the contractility of isolated malignant hyperpyrexia-susceptible porcine skeletal muscle. Br J Anaesth 1989;62:566-72. https://doi.org/10.1093/bja/62.5.566

Ilias WK, Williams CH, Fulfer RT, Dozier SE. Diltiazem inhibits halothane-induced contractions in malignant hyperthermia-susceptible muscles in vitro. Br J Anaesth 1985;57:994-6. https://doi.org/10.1093/bja/57.10.994

Foster PS, Denborough MA. The effect of calcium channel antagonists and BAY K 8644 on calcium fluxes of malignant hyperpyrexia-susceptible muscle. Int J Biochem 1993;25:495-504. https://doi.org/10.1016/0020-711x(93)90656-y

Saltzman LS, Kates RA, Corke BC, Norfleet EA, Heath KR. Hyperkalemia and Cardiovascular Collapse after Verapamil and Dantrolene Administration in Swine. Anesth Analg 1984;63:473-8. https://pubmed.ncbi.nlm.nih.gov/6711841/

Lynch C, Durbin CG Jr, Fisher NA, Veselis RA, Althaus JS. Effects of dantrolene and verapamil on atrioventricular conduction and cardiovascular performance in dogs. Anesth Analg 1986;65:252-8. https://pubmed.ncbi.nlm.nih.gov/3954091/

Keilani MR, Al-Shanableh JS. Verapamil and malignant hyperthermia - case reports. Middle East J Anaesthesiol 1985;8:37-45. https://pubmed.ncbi.nlm.nih.gov/4010529/

Rubin AS, Zablocki AD. Hyperkalemia, verapamil, and dantrolene. Anesthesiology 1987;66:246-9. https://doi.org/10.1097/00000542-198702000-00028

Migita T, Mukaida K, Yasuda T, Hamada H, Kawamoto M. Calcium channel blockers are inadequate for malignant hyperthermia crisis. J Anesth 2012;26:579–84. https://doi.org/10.1007/s00540-012-1347-0

Adnet PJ, Krivosic-Horber M, Haudecoeur G, Reyford HG, Adamantidis MM, Dupuis BA. Diltiazem and nifedipine reduce the in vitro contracture response to halothane in malignant hyperthermia-susceptible muscle. Can J Anaesth 1990;37:556-9. https://doi.org/10.1007/BF03006325

Gallant EM, Foldes FF, Rempel WE, Gronert GA. Verapamil is not a therapeutic adjunct to dantrolene in porcine malignant hyperthermia. Anesth Analg 1985;64:601-6. https://pubmed.ncbi.nlm.nih.gov/4003778/

Czuriga I, Edes I. Béta-adrenerg-receptor-blokkolók a klinikai gyakorlatban [Beta-adrenergic receptor blockers in clinical practice]. Orv Hetil 2004;145:1951-60. https://pubmed.ncbi.nlm.nih.gov/15535106/

Ording H. Influence of propranolol on the in vitro response to caffeine and halothane in malignant hyperthermia-susceptible muscle. Acta Anaesthesiol Scand 1989:33:405-8. https://doi.org/10.1111/j.1399-6576.1989.tb02933.x

Møller-Petersen J, Andersen PT, Hjørne N, Ditzel J. Nontraumatic rhabdomyolysis during diabetic ketoacidosis. Diabetologia 1986;29:229-34. https://doi.org/10.1007/BF00454881

Kilbane BJ, Mehta S, Backeljauw PF, Shanley TP, Crimmins NA. Approach to management of malignant hyperthermia-like syndrome in pediatric diabetes mellitus. Pediatr Crit Care Med 2006;7:169-73. https://doi.org/10.1097/01.PCC.0000192340.09136.82

Genetics Home Reference. Genetic Conditions. The deficiency in acyl-CoA dehydrogenase short-chain. Short-chain acyl-CoA dehydrogenase deficiency (endereço na internet). (acessado em: 2009). Disponível em: https://rarediseases.info.nih.gov/diseases/4822/short-chain-acyl-coa-dehydrogenasedeficiency#:~:text=Short%2Dchain%20acyl%2DCoA%20dehydrogenase%20(SCAD)%20deficiency%20is,acid%20oxidation%20disorders%20(FOD).

Wappler F, Scholz J, Fiege M, Kolodzie K, Kudlik C, Weibhorn R, et al. 4-Chloro-m-cresol is a Trigger of Malignant Hyperthermia in Susceptible Swine. Anesthesiology 1999;90:1733-40. https://doi.org/10.1097/00000542-199906000-00031

Freymond D, Dériaz O, Frascarolo F, Reiz S, Jéquier E, Urwyler A. In Vivo Whole-Body Resting Energy Expenditure and Insulin Action in Human Malignant Hyperthermia. Anesthesiology 2000;93:39-47. https://doi.org/10.1097/00000542-200007000-00011

Wappler F, Roewer N, Köchling A, Braune H, Reissinger T, Schulte am Esch J. Fulminant malignant hyperthermia associated with ketoacidotic diabetic coma. Intensive Care Med 1996;22:809-12. https://doi.org/10.1007/BF01709525

Hollander AS, Olney RC, Blackett PR, Marshall BA. Fatal malignant hyperthermia-like syndrome with rhabdomyolysis complicating the presentation of diabetes mellitus in adolescent males. Pediatrics 2003;111:1447-52. https://doi.org/10.1542/peds.111.6.1447

Baluch AR, Oommen SP. Malignant hyperthermia associated with diabetic hyperosmolar hyperglycemic nonketotic state in a young man. J Clin Anesth 2007;19:470-2.

https://doi.org/10.1016/j.jclinane.2006.12.008

Tammineni ER, Kraeva N, Figueroa L, Manno C, Ibarra CA, Klip A, et al. Intracellular calcium leak lowers glucose storage in human muscle, promoting hyperglycemia and diabetes. eLife 2020;9:e53999. https://doi.org/10.7554/eLife.53999

O'Leary G, Nargiso J, Weiss R. 3, 4 – methylenedioxymethamphethamine (MDMA): a Review. Curr Psychiatry Rep 2001;3:477-83. https://doi.org/10.1007/s11920-001-0041-y

Hall AP, Henry JA. Acute toxic effects of “Ecstasy” (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006;96:678-85.

https://doi.org/10.1093/bja/ael078

Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Menge M, Schulte Am Esch J. Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine ("ecstasy"). Anesthesiology 2003;99:1132-6. https://doi.org/10.1097/00000542-200311000-00020

Denborough MA, Hopkinson KC. Dantrolene and “ecstasy”. MJA 1997;166:165-6. https://doi.org/10.5694/j.1326-5377.1997.tb140056.x

Klingler W, Heffron JJA, Jurkat-Rott K, O'Sullivan G, Alt A, Schlesinger F, et al. 3,4-Methylenedioxymethamphetamine (Ecstasy) Activates Skeletal Muscle Nicotinic Acetylcholine Receptors. J Pharmacol Exp Ther 2005;314:1267-73.

https://doi.org/10.1124/jpet.105.086629

Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Esch JS. Effects of Theophylline on Anesthetized Swine Susceptible for Malignant Hyperthermia In-Vivo. Anesthesiology 2001;95:A1015. http://www.asaabstracts.com/strands/asaabstracts/abstract.htm?year=2001&index=12&absnum=1147

Gerbershagen MU, Fiege M, Weisshorn R, Kolodzie K, Wappler F. Theophyllin induziert Kontrakturen an Skelettmuskelpraparaten des Scweines mit Disposition zu Maligner Hyperthermie. Anasthesiol Intensivmed Notfallmed Schmerzther 2004;39:147-52. https://doi.org/10.1055/s-2004-814328

Mucklow JC, Kuhn S. The rise and fall of serum theophyline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance. Br J Clin Pharmacol 1985;20:589-96. https://doi.org/10.1111/j.1365-2125.1985.tb05116.x

Fiege M, Wappler F, Weisshorn R, Kolodzie K, Esch JS. In-vitro Contracture Test with Theophylline - An Alternative in Diagnosis of Malignant Hyperthermia? Anesthesiology 2002;96:A1201.

Bosetti C, Negri E, Fattore E, La Vecchia C. Occupational exposure to polychlorinated biphenyls and cancer risk. Eur J Cancer Prev 2003;12:251-5. https://doi.org/10.1097/00008469-200308000-00002

Ta TA, Pessah IN. Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2,3,5,6 –pentachlorobiphenyl (PCB 95). NeuroToxicology 2007;28:770-9. https://doi.org/10.1016/j.neuro.2006.08.007

Pessah IN, Allen PD. Malignant hyperthermia. Best Pract Res Clin Anaesthesiol 2001;15:277-88.

https://doi.org/10.1053/bean.2001.0156

Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998;49:1163-72. https://doi.org/10.1176/ps.49.9.1163

Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85:129-35.

https://doi.org/10.1093/bja/85.1.129

Hermesh H, Aizenberg D, Lapidot M, Munitz H. Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families. Am J Psychiatry 1988;145:1431-4. https://doi.org/10.1176/ajp.145.11.1431

Calore EE, Cavaliere MJ, Perez NM, Russo DH, Wakamatsu A, Razzouk D. Hyperthermic reaction to haloperidol with rigidity, associated to central core disease. Acta Neurol 1994;16:157-61. https://pubmed.ncbi.nlm.nih.gov/7856468/

Portel L, Hilbert G, Gruson D, Favier JC, Gbikpi-Benissan G, Cardinaud JP. Malignant hyperthermia and neuroleptic malignant syndrome in a patient during treatment for acute asthma. Acta Anaesthesiol Scand 1999;43:107-10. https://doi.org/10.1034/j.1399-6576.1999.430123.x

Russell T, Riazi S, Kraeva N, Steel AC, Hawryluck LA. Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene. Anaesthesia 2012;67:1021-4. https://doi.org/10.1111/j.1365-2044.2012.07226.x

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-Text Revision. 4th ed. Washington (DC): APA; 2000.

Caroff SN, Rosenberg H, Fletcher JE, Heiman-Patterson TD, Mann SC. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987;67:20-5.

https://doi.org/10.1097/00000542-198707000-00004

Tollefson G. A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia. J Clin Psychopharmacol 1982;2:266-70.

https://pubmed.ncbi.nlm.nih.gov/6126494/

Scarlett JD, Zimmerman R, Berkovic SF. Neuroleptic malignant syndrome. Aust NZ J Med 1983;13:70-3. https://doi.org/10.1111/j.1445-5994.1983.tb04554.x

Denborough MA, Collins SP, Holkinson KC. Rhabdomyolysis and malignant hyperpyrexia. Br Med J 1984;28:1878. https://doi.org/10.1136/bmj.288.6434.1878

Merry SN, Merry AF. Neuroleptic malignant syndrome and malignant hyperthermia. [Letter] N Z Med J 1988;101:431.

Krivosic-Horber R, Adnet P, Guevart E, Theunynck D, Lestavel P. Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests. Br J Anaesth 1987;59:1554-6. https://doi.org/10.1093/bja/59.12.1554

Adnet PJ, Krivosic-Horber RM, Adamantidis MM, Haudecoeur G, Adnet-Bonte CA, Saulnier F, et al. The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol Scand 1989;33:676-80. https://doi.org/10.1111/j.1399-6576.1989.tb02990.x

Silva HCA, Bahia VS, Oliveira RAA, Marchiori PE, Scaff M, Tsanaclis AMC. Susceptibilidade à hipertermia maligna em três pacientes com síndrome maligna por neurolépticos. Arq Neuropsiquiatr 2000:58:713-9. https://doi.org/10.1590/S0004-282X2000000400018

Araki M, Takagi A, Higuchi I, Sugita H. Neuroleptic malignant syndrome: caffeine contracture of single muscle fibers and muscle pathology. Neurology 1988;38:297-301.

https://doi.org/10.1212/wnl.38.2.297

Fletcher JE, Rosenberg H, Lizzo FH. Effects of droperidol, haloperidol and ketamine on halothane, succinylcholine and caffeine contractures: implications for malignant hyperthermia. Acta Anaesthesiol Scand 1989;33:187-92. https://doi.org/10.1111/j.1399-6576.1989.tb02887.x

Sato T, Nishio H, Iwata M, Kentotsuboi, Tamura A, Miyazaki T, et al. Postmortem molecular screening for mutations in ryanodine receptor type 1 (RYR1) gene in psychiatric patients suspected of having died of neuroleptic malignant syndrome. Forensic Sci Int 2010;194:77-9. https://doi.org/10.1016/j.forsciint.2009.10.014

Chen IC, Lin CS, Chou HM, Peng TH, Liu CH, Wang CF, et al. Unexpected recurrent seizures following repeated spinal injections of tetracaine - a case report. Acta Anaesthesiol Sin 2000;38:103-6. https://pubmed.ncbi.nlm.nih.gov/11000675/

Murray C, Sasaki SS, Berg D. Local anesthesia and malignant hyperthermia: review of the literature and recommendations for the dermatologic surgeon. Dermatol Surg 1999;25:626-30. https://doi.org/10.1046/j.1524-4725.1999.98214.x

Terry D. Halothane, Dental Anaesthesia and Children. Saad Digest 2000;17:26. https://pubmed.ncbi.nlm.nih.gov/11404913/

Haas DA, Young ER, Harper DG. Malignant hyperthermia and the general dentist: current recommendations. J Can Dent Assoc 1992;58:28-33. Erratum in: J Can Dent Assoc 1992;58:256. https://pubmed.ncbi.nlm.nih.gov/1531939/

Noguchi I, Ohno H, Takano K, Shimada R, Sasao M, Shimonaka H. Fatal hyperthermia due to dental treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:e61-4.

https://doi.org/10.1016/j.tripleo.2005.07.001

D'Ambrosio J, Adragna MG. Guidelines for the use of local anesthetics in the dental treatment of patients who are susceptible to malignant hyperthermia. Spec Care Dentist 1988;8:61-3. https://doi.org/10.1111/j.1754-4505.1988.tb00693.x

Nagasawa M. Effects of 4-hydroxybenzoic acid methyl ester on the Ca(2+)-related functions of skinned skeletal muscle fibers from the guinea pig. Masui 2000;49:369-75.

https://pubmed.ncbi.nlm.nih.gov/10793521/

Motegi Y, Shirai M, Arai M, Kato S, Kawana Y, Goto F. Malignant hyperthermia during epidural anesthesia. J Clin Anesth 1996;8:157-60. https://doi.org/10.1016/0952-8180(95)00204-9

Sheu CC, Tsai JR, Hung JY. Possible malignant hyperthermia during spinal anaesthesia with tetracaine. Anaesthesia 2007;62:200-1. https://doi.org/10.1111/j.1365-2044.2007.04969.x

Kemp DR, Choong LS. Malignant hyperthermia and the conscious patient. Aust N Z J Surg 1988;58:423-7.

https://doi.org/10.1111/j.1445-2197.1988.tb01092.x

Minasian A, Yagiela JA. The use of amide local anesthetics in patients susceptible to malignant hyperthermia. Oral Surg Oral Med Oral Pathol 1988;66:405-15. https://doi.org/10.1016/0030-4220(88)90256-3

Iaizzo PA, Johnson BA, Nagao K, Gallagher WJ. 4-chloro-m-cresol triggers malignant hyperthermia in susceptible swine at doses greatly exceeding those found in drug preparations. Anesthesiology 1999;90:1723-32. https://doi.org/10.1097/00000542-199906000-00030

Lichtman AD, Oribabor C. Malignant hyperthermia following systemic rewarming after hypothermic cardiopulmonary bypass. Anesth Analg 2006;102:372-5.

https://doi.org/10.1213/01.ane.0000189596.70694.36

Baur CP, Bellon L, Felleiter P, Fiege M, Fricker R, Glahn K, et al. A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility. Anesth Analg 2000;90:200-5. https://doi.org/10.1097/00000539-200001000-00040

Wappler F, Anetseder M, Baur CP, Censier K, Doetsch S, Felleiter P, et al. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility. Eur J Anaesthesiol 2003;20:528-36. https://doi.org/10.1017/s026502150300084x

Anetseder M, Ritter L, Horbaschek H, Hartung E, Roewer N. The impact of 4-chloro-m-cresol in heparin formulas on malignant hyperthermia: in vitro and in vivo. Acta Anaesthesiol Scand 2000;44:338-42. https://doi.org/10.1034/j.1399-6576.2000.440321.x

Downloads

Publicado

2021-09-20

Como Citar

Rodrigues, G., & Silva, H. C. A. da. (2021). Elaboração de Manual de Orientações sobre Hipertermia Maligna para Pacientes. Revista Neurociências, 29, 1–59. https://doi.org/10.34024/rnc.2021.v29.12345

Edição

Seção

Artigos de Revisão
Recebido em 2021-06-25
Aceito em 2021-07-28
Publicado em 2021-09-20

Artigos mais lidos pelo mesmo(s) autor(es)